YONGIN, South Korea, December 11, 2024 /PRNewswire/ — Noul Co., Ltd. (CEO: David Lim, hereinafter “Noul”) has signed an agreement with Limbach Group SE, the largest laboratory chain in Germany, to report for the launch of the miLab platform in the EU.

Under the agreement, Noul will provide its AI-based hematology solution, miLab BCM, and its malaria diagnostic solution, miLab MAL, for phased implementation in Limbach Group laboratories. The miLab BCM is an AI-based blood testing solution, while the miLab MAL specializes in AI-based malaria diagnosis in samples.

Noul CEO David Lim said: “This agreement is significant as it is the first contract with a major laboratory chain in Europe” and that “Noul plans to expand its reach into the European market with all its test portfolios, starting with the well-referenced miLab MAL and BCM, and in the near future with the solution for cervical cancer recognized by WHO-UNITAID. Obtaining the most esteemed and high profile reference clients in Europe will accelerate our expansion into other countries in the region.

The Limbach Group is the largest clinical laboratory network in Germany and one of the largest networks in Europe with 300 clinical specialists and more than 5,000 employees, generating more than 1.2 billion euros in revenue. business. Limbach Laboratories provide premier services in all areas of laboratory diagnostics, including immunology and hematology. Through this partnership, Noul has established the foundation to provide patients with more effective on-device AI solutions for BCM and MAL than ever before. Starting with Germany, Noul plans to expand its supply chain throughout Europe, including Switzerland and the Netherlands.

Logo-

Show original content: